Personalized catheter plan aims to cut Re-Insertions after rectal cancer surgery
NCT ID NCT07346586
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a personalized plan for removing urinary catheters after mid-low rectal cancer surgery can reduce the need for re-insertion. About 1,545 patients will be randomly assigned to one of three groups: catheter removal at 24 hours, at 48 hours, or an individualized plan where high-risk patients get a medication (tamsulosin) before removal. The main goal is to see which strategy leads to the fewest patients needing a new catheter within a week.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tamsulosin
- What this could lead to
- If successful, this could lead to a standard, personalized plan for removing urinary catheters earlier after rectal cancer surgery, reducing discomfort and infection risk.
- What could go wrong
- This is a single-center trial that hasn't started yet. The results may not apply to all hospitals, and the personalized approach may not lower re-catheterization rates as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,545 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients with a preoperative pathological confirmation of rectal malignant tumor. 2. Preoperative colorectal CT or rectal MRI confirming that the lower edge of the tumor is located in the rectum within 10 cm from the anal verge (including rectal and anal canal lesions). 3. Patients scheduled to undergo laparoscopic or robot-assisted radical total mesorectal excision (TME). Exclusion Criteria: 1. History of previous abdominal surgery involving the rectum/sigmoid colon/left colon, bladder resection or partial resection, prostate surgery (in males), or hysterectomy (in females). 2. History of urethral trauma, intracranial surgery, spinal surgery, cerebral infarction with limb dysfunction, or Parkinson's disease. 3. Inability to void urethrally preoperatively due to any reason (e.g., ureteral puncture, ureterostomy). 4. Previously diagnosed overactive bladder syndrome, prior AUR or voiding dysfunction, or diabetic cystopathy. 5. Preoperative assessment indicating potential need for combined resection of other pelvic organs during surgery, including the bladder, prostate, uterus and cervix, or vagina (excluding simple adnexectomy in females). 6. Preoperative assessment indicating potential need for lateral pelvic lymph node dissection. 7. Preoperative renal insufficiency (serum creatinine level \>133 μmol/L). 8. Patients undergoing emergency surgery. 9. Male patients with preoperative benign prostatic hyperplasia requiring medication. 10. Presence of indwelling ureteral stents, ureteral stenosis, or bilateral hydronephrosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy added to standard treatment aims to save the anus in Ultra-Low rectal cancer
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Prostate drug tested to stop urinary problems after rectal surgery
- Can two immunotherapy drugs help rectal cancer patients skip pelvic radiation?
- Can digital surveys capture the full toll of rectal cancer treatment?
- Can a targeted drug conjugate outsmart advanced colorectal cancer?